Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.39 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.39 |
| ▸ | KDM6B | O15054 | 2/20 | 0.39 |
| ▸ | KDM5C | P41229 | 2/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL8002651 | 1.00 | EGLN1 (0.39) | EGLN1LMNAALKBH5SUCNR1KDM6B | |
| Succinic Acid SCHEMBL1871339 | 0.96 | EGLN1 (0.36) | EGLN1LMNAALKBH5SUCNR1KDM6B | |
| SCHEMBL9241914 | 0.96 | EGLN1 (0.36) | EGLN1LMNAALKBH5SUCNR1KDM6B | |
| SCHEMBL1989298 | 0.96 | ALDH1A1 (0.39) | EGLN1LMNAALKBH5SUCNR1KDM6B | |
| SCHEMBL27076088 | 0.93 | ALDH1A1 (0.37) | EGLN1KDM6BKDM5CPHF8KDM2A | |
| SCHEMBL28452924 | 0.93 | ALDH1A1 (0.37) | EGLN1KDM6BKDM5CPHF8KDM2A | |
| SCHEMBL11245866 | 0.91 | ALDH1A1 (0.36) | EGLN1KDM6BKDM5CPHF8KDM2A | |
| Pyruvate SCHEMBL14485736 | 0.91 | EGLN1 (0.37) | EGLN1LMNAALKBH5SUCNR1KDM6B | |
| Succinic Acid SCHEMBL11064867 | 0.90 | TSHR (0.46) | LMNAALDH1A1TSHROR51E2SLC22A6 | |
| SCHEMBL5158691 | 0.89 | LMNA (0.46) | LMNAALDH1A1TSHRCYP2D6SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117695279-A | Loratadine composition and loratadine medicament | 九华华源药业(桂林)有限公司 | 2024-03-15 | — | — | CN | claimed |
| EP-1878421-B1 | EXTERNAL PREPARATION FOR SKIN | SBI PHARMACEUTICALS CO LTD (JP) | 2019-04-03 | — | — | EP | claimed |
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-08-09 | — | — | US | claimed |
| EP-2424568-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USE | University Of Kentucky Research Foundation (US) | 2012-03-07 | — | — | EP | claimed |
| US-7939104-B2 | Granulation; compaction; rapid dissolution upon contact with physiological solvents such as water, saliva or gastrointestinal fluids | SANDOZ AG (CH) | 2011-05-10 | — | — | US | claimed |
| WO-2010126501-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-11-04 | — | — | WO | claimed |
| US-20080146581-A1 | Solubility of hydrophobic drugs with a compound having a carboxylic acid moiety | SANDOZ AG (CH) | 2008-06-19 | — | — | US | claimed |
| US-20050249814-A1 | Solubility of hydrophobic drugs with a compound having a carboxylic acid moiety | SANDOZ AG (CH) | 2005-11-10 | — | — | US | claimed |
| US-6825570-B2 | Resistance-reducing conductive adhesives for attachment of electronic components | MICRON TECHNOLOGY, INC. | 2004-11-30 | — | — | US | claimed |
| US-20030044873-A1 | Test strip for determining dialysate composition | SERIM RESEARCH CORPORATION | 2003-03-06 | — | — | US | claimed |
| CN-1088777-A | The preparation method that is used for the chemotherapeutic preparation of directly administering to cancer nidus | CONG FANZI (CN) | 1994-07-06 | — | — | CN | claimed |
| US-5164307-A | Biosynthesis | AJINOMOTO CO., INC. (JP) | 1992-11-17 | — | — | US | claimed |
| US-20230357220-A1 | 3-((1H-PYRAZOL-4-YL)METHYL)-6′-(PHENYL)-2H-(1,2′-BIPYRIDIN)-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR USE IN A METHOD OF TREATMENT OF E.G. DEPRESSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20230348435-A1 | 1-((1H-PYRAZOL-4-YL)METHYL)-3-(PHENYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR THE TREATMENT OF E.G. DEPRESSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230271974-A1 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | ABBVIE INC. | 2023-08-31 | — | — | US | disclosed |
| EP-4153583-A1 | 1-((1H-PYRAZOL-4-YL)METHYL)-3-(PHENYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR THE TREATMENT OF E.G. DEPRESSION | Takeda Pharmaceutical Company Limited (JP) | 2023-03-29 | — | — | EP | disclosed |
| WO-1990014235-A1 | HEAT-SENSITIVE RECORD MATERIAL | SMITH & MCLAURIN LIMITED (GB) | 1990-11-29 | — | — | WO | disclosed |
| EP-0399953-A2 | Piperidine-triazine compounds for use as stabilizers for organic materials | CIBA-GEIGY AG (CH) | 1990-11-28 | — | — | EP | disclosed |
| EP-0395584-A2 | Piperidine-triazine compounds for use as stabilizers for organic materials | CIBA-GEIGY AG (CH) | 1990-10-31 | — | — | EP | disclosed |
| US-4113858-A | POLYPEPTIDES, MULTIPLE SCLEROSIS | ST. LUKE'S HOSPITAL (US) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271974-A1 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | TSLP, HRH4, IL4 | EGLN1 3103/4885LMNA 3035/4885ALKBH5 1961/4885 |
| US-20080146581-A1 | Solubility of hydrophobic drugs with a compound having a carboxylic acid moiety | ABCG2, ABCB11, SLC10A1 | EGLN1 3866/4885LMNA 4775/4885ALKBH5 4716/4885 |
| US-20230348435-A1 | 1-((1H-PYRAZOL-4-YL)METHYL)-3-(PHENYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR THE TREATMENT OF E.G. DEPRESSION | GPR139, GPR142, HTR2C | EGLN1 3176/4885LMNA 4728/4885ALKBH5 3707/4885 |
| US-20230357220-A1 | 3-((1H-PYRAZOL-4-YL)METHYL)-6′-(PHENYL)-2H-(1,2′-BIPYRIDIN)-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR USE IN A METHOD OF TREATMENT OF E.G. DEPRESSION | GPR139, GPR142, OPRL1 | EGLN1 3973/4885LMNA 4725/4885ALKBH5 3920/4885 |
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | CNR2, CNR1, FAAH | EGLN1 1500/4885LMNA 1856/4885ALKBH5 3968/4885 |
| US-20050249814-A1 | Solubility of hydrophobic drugs with a compound having a carboxylic acid moiety | ABCG2, ABCB11, SLC10A1 | EGLN1 3866/4885LMNA 4775/4885ALKBH5 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.